Design Therapeutics (DSGN) Change in Cash (2020 - 2026)
Design Therapeutics (DSGN) reported Change in Cash of -$4.1 million for Q1 2026, up 54.07% on a YoY basis from -$2.7 million in Q1 2025, and down 331.11% sequentially from $1.8 million in Q4 2025.
Design Therapeutics (DSGN) Change in Cash (2020 - 2026) Analysis & Trends
Design Therapeutics (DSGN) has 7 years of Change in Cash data on file, last reported at -$4.1 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Cash rose 54.07% year-over-year to -$4.1 million; the trailing twelve-month figure through Mar 2026 stood at -$897000.0 (up 94.3% YoY), and the FY2025 full-year result was -$5.7 million, down 518.71% from the prior year.
- Change in Cash declined to -$4.1 million in Q1 2026, from $1.8 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $16.3 million in Q2 2024 to a low of -$167.7 million in Q2 2022.
- A 5-year average of -$16.8 million and a median of -$4.6 million in 2025 frame the typical range for Change in Cash.
- Peak annual rise in Change in Cash reached 1111.29% in 2024, while the deepest fall reached 2163.22% in 2024.
- Tracing DSGN's Change in Cash over 5 years: stood at -$16.0 million in 2022, then surged by 57.91% to -$6.7 million in 2023, then retreated by 15.17% to -$7.8 million in 2024, then jumped by 122.77% to $1.8 million in 2025, then sank by 331.11% to -$4.1 million in 2026.
- Business Quant data shows DSGN's Change in Cash at -$4.1 million in Q1 2026, $1.8 million in Q4 2025, and -$4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -22.03 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 243.78 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 417.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -153.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Design Therapeutics | 714.48 Mn | 491.66 Mn | - | -4.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.09 Mn |
| Dec 31, 2025 | 1.77 Mn |
| Sep 30, 2025 | -4.62 Mn |
| Jun 30, 2025 | 6.04 Mn |
| Mar 31, 2025 | -8.90 Mn |
| Dec 31, 2024 | -7.77 Mn |
| Sep 30, 2024 | -15.37 Mn |
| Jun 30, 2024 | 16.30 Mn |
| Mar 31, 2024 | 8.20 Mn |
| Dec 31, 2023 | -6.74 Mn |
| Sep 30, 2023 | 745,000.00 |
| Jun 30, 2023 | -1.61 Mn |
| Mar 31, 2023 | 2.31 Mn |
| Dec 31, 2022 | -16.02 Mn |
| Sep 30, 2022 | -77.14 Mn |
| Jun 30, 2022 | -167.66 Mn |
| Mar 31, 2022 | -11.26 Mn |
| Dec 31, 2021 | -59.09 Mn |
| Sep 30, 2021 | -13.18 Mn |
| Jun 30, 2021 | -29.86 Mn |